Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
SOUTH SAN FRANCISCO, Calif., March 11, 2016 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Executive Vice President and Chief Business Officer, will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2016 at 10:45 AM Eastern Daylight Time.
The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at https://cc.talkpoint.com/barc002/031516a_ae/?entity=133_M336FR1. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe, Investor Relations 415-365-5737 [email protected]
